LOC342918 Inhibitors
LOC342918 inhibitors encompass a variety of compounds that function by disrupting specific cellular pathways which are essential for the activity of LOC342918. Staurosporine is a prominent kinase inhibitor that, by targeting protein kinase C (PKC), could disrupt multiple signaling cascades potentially responsible for LOC342918 activation. The disruption of PKC signaling by Staurosporine would impede any PKC-mediated phosphorylation events that might be required for LOC342918 function. Triciribine, an inhibitor of AKT, suppresses the phosphorylation and activation of AKT, a kinase central to numerous cell survival and growth pathways. If LOC342918 functions downstream of AKT, the suppression of these pathways would logically lead to a reduction in LOC342918 activity.
Palbociclib, ZM-447439, and PD0332991 are inhibitors of cell cycle kinases such as CDK4/6 and Aurora kinases. These inhibitors arrest cell cycle progression and impede mitotic events, respectively. If LOC342918 is involved in cell cycle regulation or participates in mitotic processes, the inhibition of these kinases would reduce LOC342918 activity. AZD7762, a CHK1 inhibitor, obstructs cell cycle checkpoints, which would impact LOC342918 if it is involved in the checkpoint-regulated DNA damage response. Similarly, Olaparib functions by inhibiting PARP, which is crucial for DNA repair. Inhibition of PARP would decrease LOC342918 activity if LOC342918 has a role in DNA repair mechanisms.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that targets multiple kinases including PKC, which is often upstream of various signaling cascades. Staurosporine inhibition of PKC would disrupt signaling events leading to the activation of LOC342918 if PKC is implicated in its activation. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
AKT inhibitor that prevents phosphorylation and activation of AKT. Since AKT is a central node in cell survival pathways, Triciribine would diminish these survival pathways, leading to decreased activation of LOC342918 if it is downstream of AKT. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor that arrests cell cycle progression. By halting the cell cycle, Palbociclib would indirectly reduce LOC342918 activity if LOC342918 is involved in cell cycle regulation. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
Aurora kinase inhibitor that impedes mitotic progression. Inhibition of Aurora kinases would decrease LOC342918 activity if LOC342918 has a role in mitotic events. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
CHK1 inhibitor that blocks cell cycle checkpoints. AZD7762 would reduce LOC342918 activity if LOC342918 is part of the DNA damage response pathway regulated by CHK1. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
PARP inhibitor that impedes DNA repair. By inhibiting PARP, Olaparib could decrease LOC342918 activity if LOC342918 is involved in the DNA repair processes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor that disrupts protein degradation. Bortezomib could reduce LOC342918 activity if LOC342918 is regulated by proteasomal degradation. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
MDM2 antagonist that stabilizes p53. Nutlin-3 could diminish LOC342918 activity if LOC342918 is negatively regulated by p53 signaling. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
Dual PI3K/mTOR inhibitor that disrupts signaling for cell growth and survival. PI-103 could inhibit LOC342918 activity if it is downstream of the PI3K/mTOR pathway. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $62.00 $87.00 | 4 | |
Inhibitor of Aurora kinases that prevents cell division. VX-680 would inhibit LOC342918 activity if LOC342918 is implicated in cell cycle progression and mitosis. | ||||||